The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer 1,2, who were germline BRCA1 and BRCA2 wild type 3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P < 0.001), and OS was 96% and 83% (log-rank P < 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type. ClinicalTrials.gov ID: NCT03150576.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For instance, the PARTNER trial reported no added benefit of olaparib when combined with neoadjuvant carboplatin/paclitaxel in BRCA-proficient TNBC, showing no improvement in pCR, event-free survival (EFS), or OS [58].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“For instance, neoadjuvant paclitaxel plus carboplatin achieved a pCR of 52% and a 36-month EFS of 79% in the PARTNER trial (NCT03150576) [58, 59].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“synthetic lethality by preventing repair of single-strand breaks, which leads to problems downstream with double-strand repair 15,16 .”
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · cited 1×
“synthetic lethality by preventing repair of single-strand breaks, which leads to problems downstream with double-strand repair 15,16 .”
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Self-citationPembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888 · cited 1×
“The CREATE-X trial demonstrated a significant benefit in patients with TNBC from 6 months of adjuvant capecitabine given after neoadjuvant chemotherapy that left residual disease 25 .”
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
Arun, B., Couch, F. J., Abraham, J., Tung, N., & Fasching, P. A. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02827-z · Cited by 97
“…did not improve pCR rates, event-free survival (EFS) or OS compared with paclitaxel and carboplatin alone among patients with non-gBRCAm and TNBC [46], improvements in EFS and OS were observed among patients with gBRCAm who received a gap schedule of olaparib with paclitaxel and carboplatin [45].”
BackgroundMethodSelf-citationHerencia-Ropero, A., Llop‐Guevara, A., Staniszewska, A. D., Domènech-Vivó, J., García‐Galea, E., Moles‐Fernández, A., Pedretti, F., Domènech, H., Rodríguez, O., Guzmán, M., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01370-z · Cited by 90
Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond
Agelidis, A. M., Ter‐Zakarian, A., & Jaloudi, M. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s516125 · Cited by 67
Basyuni, S., Heskin, L., Degasperi, A., Black, D., Koh, C. C., Chmelova, L., Rinaldi, G., Bell, S., Grybowicz, L., Elgar, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51577-2 · Cited by 48
Self-citationZheng, Y., Zhang, T., Chang, M., Xia, L., Chen, L., Ding, L., Chen, Y., & Wu, R. (2024) · Advanced Materials · doi:10.1002/adma.202413601 · Cited by 47
Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors
Chehade, C. H., Gebrael, G., Sayegh, N., Özay, Z. İ., Narang, A., Crispino, T., Golan, T., Litton, J. K., Swami, U., Moore, K. N., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21870 · Cited by 50
Schwarzhans, F., George, G., Sánchez, L. E., Zaric, O., Abraham, J., Woitek, R., & Hatamikia, S. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.112086 · Cited by 40
Self-citationAbraham, J., O’Connor, L. O., Grybowicz, L., Pinilla, K., Dayimu, A., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59151-0 · Cited by 29
“In neoadjuvant chemotherapy given before surgery, the pathological complete response (pCR) endpoint, de fi ned as no invasive cancer at surgery in the breast and axilla, has been shown in TNBC to be associated with improved survival outcomes 13,14 .”
Self-citationClinico-pathological factors predicting pathological response in early triple-negative breast cancer
Helal, C., Djerroudi, L., Ramtohul, T., Laas, E., Vincent‐Salomon, A., Jin, M., Seban, R., Bièche, I., Bello-Roufai, D., Bidard, F., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00729-8 · Cited by 30
“…with germline BRCA1/2 mutations may bene fi t from a de-escalation strategy with the use of PARP inhibitors + / − ICI in the neoadjuvant setting 39,40 , and consideration of salvage chemotherapy in the absence of pCR. TNBCisahighlyproliferativebreastcancersubtype,usuallyassociated with high…”
Impact of Molecular Profiling on Therapy Management in Breast Cancer
Ultimescu, F., Hudiță, A., Popa, D. E., Olincă, M., Muresean, H. A., Ceaușu, M. C., Stanciu, D. I., Ginghină, O., & Gălățeanu, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13174995 · Cited by 26
“Based on these results, Margetuximab has received FDA approval for treating HER2-low metastatic BC along with chemotherapy for patients who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease [75].”
BackgroundBreast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention
Lei, H., Fu, J., Gu, W., Qiao, H., Guo, H., Chen, Z., Wang, S. M., & Chen, T. (2026) · MedComm · doi:10.1002/mco2.70560 · Cited by 24
Zeng, Z., Tian, J., Xu, W., Liu, H., Xiang, D., Liao, D., Wu, J., & Chen, C. (2024) · Materials & Design · doi:10.1016/j.matdes.2024.113270 · Cited by 18
Habaka, M., Daly, G. R., Shinyanbola, D., Alabdulrahman, M., McGrath, J., Dowling, G. P., Hehir, C. M., Huang, H. Y. R., Hill, A. D. K., Varešlija, D., et al. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01669-z · Cited by 17
“The PARTNER trial, which evaluated olaparib with paclitaxel and carboplatin, demonstrated comparable pCR rates to the control group receiving paclitaxel and carboplatin alone (51% vs 52%, HR 1.02, 95% CI 0.75–1.39) [ 62].”
InfluentialGene context drift identifies drug targets to mitigate cancer treatment resistance
Jassim, A., Nimmervoll, B. V., Terranova, S., Nathan, E., Hu, L., Taylor, J., Masih, K. E., Ruff, L., Duarte, M., Cooper, E., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.005 · Cited by 17
“…tumors, and to test if gene context drift can be detected immediately following treatment, rather than after relapse, we analyzed snRNA-seq profiles of TNBC generated from 47 women before, and immediately following, neoadjuvant chemotherapy as part of the PARTNER clinical trial 45,46 (Figure 7B).”
Self-citationTriple-Negative Breast Cancer Unveiled: Bridging Science, Treatment Strategy, and Economic Aspects
Lebedeva, V., Ebbinghaus, M., Hidalgo, J. V., Hardt, O., & Pfeifer, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199714 · Cited by 15
“However, the PARTNER trial (NCT03150576) showed that adding olaparib to chemotherapy did not improve the outcomes for gBRCA1/2 wild-type mTNBC [97].”
Blackmur, J. P., van der Mijn, J. C. K., Warren, A. Y., Browning, L., Burgers, F. H., Hirsch, M. S., Kapur, P., Mehra, R., Rao, P., Signoretti, S., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00345-6 · Cited by 15
Shea, A., Lubling, Y., Guerrero-Romero, D., García, R. M., Greenwood, W., O’Reilly, M., Georgopoulou, D., Callari, M., Lerda, G., Wix, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1703 · Cited by 13
Self-citationXiang, J., Li, J., Guo, Z., Wu, J., Ma, D., Xu, H., Shang, T., Pu, P., Cong, L., Zhou, R., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00908-0 · Cited by 12
Zhu, S., Sun, C., Cai, Z., Wu, J., Han, X., Wang, J., & Wang, C. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113601 · Cited by 11
Fasching, P. A., Schmatloch, S., Hauke, J., Rey, J., Jackisch, C., Klare, P., Link, T., Hanusch, C. A., Huober, J., Stefek, A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2806 · Cited by 12
Zhang, Z., Tian, F., Lai, S., Xu, X., Zhou, M., Hou, Z., Li, S., Zhang, J., Yang, X. F., Xie, J., et al. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00071h · Cited by 7
Zhang, H., Geng, R., Zheng, B., Zhang, Z., Zhao, Z., Hu, Y., & Ma, X. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.172476 · Cited by 5
Coleman, N., Harvey, R. D., Hong, D. S., & LoRusso, P. M. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1356 · Cited by 6
Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy
Previtali, A., Guardamagna, I., Calandra, S., Shakarami, M., Lonati, L., Riani, C., Semerano, R., Baiocco, G., Maggi, M., & Scotti, C. (2026) · Cancers · doi:10.3390/cancers18040618 · Cited by 5
Teng, Y., Yang, L., Luo, H., Tang, M., Song, J., Gou, L., Xiao, Y., Cui, X., Yang, T., Cen, X., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03804 · Cited by 4
Lafcı, O., Resch, D., Santonocito, A., Clauser, P., Helbich, T. H., & Baltzer, P. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.112105 · Cited by 5
Tang, J., Liu, Q., Du, W., Chen, L., Qi, F., Zhang, R., Hoang, B. H., Geller, D. S., Yang, R., Wang, J., et al. (2025) · Bioengineering · doi:10.3390/bioengineering12060586 · Cited by 4
“Additionally, multiple clinical trials, such as PARTNER [45], are now exploring their potential application in breast cancers without BRCA mutations.”
Yusoh, N. A., Su, L., Chia, S. L., Tian, X., Ahmad, H., & Gill, M. R. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70093 · Cited by 4
“For instance, the PARTNER clinical trial assessing neoadjuvant Olaparib with carboplatin/paclitaxel treatment in BRCA-proficient TNBC patients found no clinical benefit [60].”
Li, W., Chang, Y.-W., Bai, X., & Cao, H. (2024) · American Journal of Translational Research · doi:10.62347/vhme8736 · Cited by 3
“The base-line data and laboratory indicators were compared between patients; and a nomogram model was constructed to visualize independent prognostic factors for DFS [17].”
MethodQin, W., Shao, L., Li, Q., Zhang, D., Jia, X., & Dong, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02503-7 · Cited by 3
“Chemotherapy remains the primary clinical treatment for TNBC, as it can enhance surgical success rates and achieve pathological remission [2].”
Dai, Y., Pan, X., Guo, S., Ji, S., Cao, S., Montierth, M. D., Jiang, Y., Chang, J. T., Shi, L., Shalapour, S., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102610 · Cited by 7
Current and future therapies for triple-negative breast cancer
Wang, Z.-X., Liu, X., Wu, Y., Xiao, Y.-L., Ge, L., Wu, S., Jiang, Y., & Shao, Z.-M. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01839-x · Cited by 3
Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation
Camps-Fajol, C., Minguillón, J., & Surrallés, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02954-4 · Cited by 3
“This was based on the international OlympiA Phase III trial (NCT02032823) studying 1836 patients with high-risk g BRCA1/2 m HER2-early breast cancer receiving 1 year of adjuvant olaparib after completion of de fi nitive local treatment and neoadjuvant or adjuvant CTx. Results showed that patients treated with olaparib…”
InfluentialYu, H., & Wei, L. (2025) · Oncology Letters · doi:10.3892/ol.2025.14961 · Cited by 4
Ratanaphan, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209881 · Cited by 4
“PARP inhibitors induce synthetic lethality by inhibiting PARP1/2 catalytic activity, preventing the repair of single-strand DNA breaks (SSBs) and leading to their accumulation.”
Niu, J., Tuo, X., Xu, H., Li, M., Liu, S., Zhang, Z., Tang, J., Lu, Y., & Yang, K. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70037 · Cited by 2
Progress toward personalized management of stage II/III triple negative breast cancer
Valle, I., Ribeiro, J. M., Grinda, T., Kok, M., Pistilli, B., Werutsky, G., & Rassy, E. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103143 · Cited by 3
Thérapies ciblées en situation néoadjuvante dans le cancer du sein : place des iCDK4/6 et des iPARP
Papazyan, T., & Frenel, J. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.06.005 · Cited by 1
Yang, F., Li, S., Chen, F., Ji, Q., Wu, Y., Zhang, F., Wang, Y., Luo, C., & Li, S. (2026) · Materials Today · doi:10.1016/j.mattod.2026.103261 · Cited by 1
Hutten, S. J., Chao, X., Badoux, M., Eijkman, T., Sheinman, M., de Bruijn, R., Herencia-Ropero, A., Llop‐Guevara, A., Lutz, C., Wesseling, J., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ads9088 · Cited by 1
Antonini, M., Mattar, A. P. L., Madeira, M., Cavalcante, F. P., Zerwes, F., Brenelli, F. P., Frasson, A. L., Millen, E. C., Tosello, G. T., Teixeira, M. D., et al. (2026) · Clinical Breast Cancer · doi:10.1016/j.clbc.2026.04.016 · Cited by 1
Ravani, L. V., Wander, S. A., Kok, M., McCann, K. E., Cortés, J., Barroso‐Sousa, R., Lustberg, M. B., Bines, J., Michelon, I. F., Testa, L., et al. (2026) · Breast Cancer Research and Treatment · doi:10.1007/s10549-026-07963-z · Cited by 1
Prognostic and predictive value of HRD in early triple negative breast cancer (TNBC)
Esposto, R., Marchi, L. D., Bonotto, M., Bortot, L., Poletto, E., Aprile, G., Cesselli, D., Puglisi, F., & Minisini, A. M. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105447 · Cited by 1
Wei, C., Liu, S., Hu, J., Cao, B., & Liu, B. (2026) · BMC Cancer · doi:10.1186/s12885-026-16520-2 · Cited by 1
Huynh, A. M. T., Lei, J. T., Brough, R., Sallas, C., Xu, J., Pilcher, J. B., Gou, X., Wang, J., Dobrolecki, L. E., Fandino, D. M., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-26-0182 · Cited by 1
Cheng, H., Chen, Y., Liu, P.-Y., Jin, X., Qu, Y., Liu, B., & Ai-zhuo, L. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01892-9 · Cited by 1
Rafaeva, M., Kaczyńska, B., Redondo-Pedraza, J., Bentires‐Alj, M., Khaled, W. T., & Fré, S. (2024) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-024-09572-2 · Cited by 1
Foidart, P., & Jérusalem, G. (2025) · Gland Surgery · doi:10.21037/gs-24-467 · Cited by 1
Kapur, P., Christie, A. L., Jarmale, V. N., Tahmasebi, F., Xie, B., Miyata, J., Rakheja, D., Cadeddu, J. A., Margulis, V., Hammers, H. J., et al. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101069
Stable survival extrapolation using mortality projections
Apsemidis, A., & Demiris, N. (2025) · Biometrics · doi:10.1093/biomtc/ujaf159 · Cited by 1
Self-citationm6A modified circPTK2 mediates TNBC chemotherapy resistance
Yuan, J., Xie, B., Wen, X., Zhao, G., & Shen, H. (2026) · Translational Cancer Research · doi:10.21037/tcr-2025-1-2634
“Among them, the breast cancer susceptibility gene 1 (breast cancer susceptibility gene 1, BRCA1) is regarded as an important molecular factor contributing to DDP resistance in TNBC (15). circRNAs exhibit specific expression in different developmental stages and tissues.”
Zhang, B., Wang, Y., Fang, Y., Wang, Y., & Feng, M. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2026.103222
Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights
Aloss, K., Frederick, M. I., & Hassan, S. N. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-00963-8
Li, B., Tian, X., Yu, Q., & Cui, H. (2026) · Oncology Letters · doi:10.3892/ol.2026.15775
“In PARTNER, a randomized clinical trial, adding olaparib to platinum‑based neoadjuvant chemotherapy in germline BRCA wild‑type TNBC did not improve pCR, EFS or OS (50), meaning that knowledge of a plausible mecha‑ nism is not sufficient.”
Cancer cell-platelet interactions: Harnessing therapeutic opportunities in cancer treatment
Jain, S., & Rao, G. S. N. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27731-3.00013-9
Silva, J., Costa, P., & Beatriz, A. (2024) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/xex7ntytng
Schouten, P. C., Irfan, M. O., Kinsella, Z., Sionakidis, A., Riddell, A., Worley, J. R., Lay, J., Casford, S., Pinilla, K., Kane, J., et al. (2026) · medRxiv · doi:10.64898/2026.09.15.26363116
Self-citationTumor digital twins uncover therapeutic strategies in triple-negative breast cancer
Victori, P., Hua, K., Twigger, A., Anand, A., Bose, Z. M., Clarke, M. A., Bell, S., Xian, K. J. Q., Zakarneh, L., Pinilla, K., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103119
Self-citationYaringaño, J., Pimentel, I., Thomas-Bonafos, T., Oliveira, M., Saura, C., Ouali, K., Grinda, T., Rassy, E., Pistilli, B., Balmaña, J., et al. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103242
Metadata
- Authors
- Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., Worley, J. R., Chhabra, A., Qian, W., Vallier, A.-L., Hardy, R. M., Chan, S., Hickish, T., Tripathi, D., Venkitaraman, R., Persic, M., Aslam, S., Glassman, D., Raj, S., Borley, A., Braybrooke, J. P., Sutherland, S., Staples, E., Scott, L. C., Davies, M., Palmer, C. A., Moody, M., Churn, M. J., Newby, J. C., Mukesh, M. B., Chakrabarti, A., Roylance, R. R., Schouten, P. C., Levitt, N. C., McAdam, K., Armstrong, A. C., Copson, E. R., McMurtry, E., Tischkowitz, M., Provenzano, E., & Earl, H. M.
- Affiliations
- University of Cambridge (GB)
- Athens University of Economics and Business (GR)
- Royal Devon University Healthcare NHS Foundation Trust (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Nottingham University Hospitals NHS Trust (GB)
- Royal Bournemouth Hospital (GB)
- Russells Hall Hospital (GB)
- East Suffolk and North Essex NHS Foundation Trust (GB)
- University Hospitals of Derby and Burton NHS Foundation Trust (GB)
- Bedford Hospital NHS Trust (GB)
- Pinderfields Hospital (GB)
- Royal Hampshire County Hospital (GB)
- Velindre Cancer Centre (GB)
- University Hospitals Bristol and Weston NHS Foundation Trust (GB)
- Mount Vernon Hospital (GB)
- Barking, Havering And Redbridge University Hospitals NHS Trust (GB)
- Beatson West of Scotland Cancer Centre (GB)
- Swansea Bay University Health Board (GB)
- Hinchingbrooke Hospital (GB)
- West Suffolk NHS Foundation Trust (GB)
- Worcestershire Acute Hospitals NHS Trust (GB)
- Royal Free London NHS Foundation Trust (GB)
- Poole Hospital (GB)
- University College London Hospitals NHS Foundation Trust (GB)
- Oxford University Hospitals NHS Trust (GB)
- Peterborough City Hospital (GB)
- The Christie NHS Foundation Trust (GB)
- University of Southampton (GB)
- Corresponding author
- Abraham, Jean E.
- ORCID
- Abraham, Jean E.
- Pinilla, Karen
- Dayimu, Alimu
- Grybowicz, Louise
- Lucey, Rebecca
- Fulton, Alexander
- Chhabra, Anita
- Qian, Wendi
- Hickish, Tamas
- Tripathi, Devashish
- Venkitaraman, Ramachandran
- Borley, Annabel
- Braybrooke, Jeremy P.
- Churn, Mark J.
- Chakrabarti, Amitabha
- Roylance, Rebecca R.
- Schouten, Philip C.
- McAdam, Karen
- Armstrong, Anne C.
- Copson, Ellen R.
- Tischkowitz, Marc
- Provenzano, Elena
- Earl, Helena M.
- Venue
- Nature
- Published
- 2024-04-08
- Volume
- 629
- Issue
- 8014
- Pages
- 1142-1148
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC11136660
- OpenAlex
- W4394580299
- Cited by
- 53
- References
- 36
- Citations by year
- 2026: 20 · 2025: 22 · 2024: 11
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- olaparib, triple-negative breast cancer, neoadjuvant therapy, PARP inhibitors, carboplatin, paclitaxel, anthracycline chemotherapy, pathological complete response, event-free survival, overall survival
- MeSH terms
- Progression-Free Survival, Pathologic Complete Response, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Middle Aged, Phthalazines, Piperazines, Prospective Studies, Time Factors, Survival Analysis, Carboplatin, Paclitaxel, Germ-Line Mutation, Anthracyclines, BRCA1 Protein, Genes, BRCA1, Neoadjuvant Therapy, Genes, BRCA2, BRCA2 Protein, Young Adult, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.